P

Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403

Watchlist Manager
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Watchlist
Price: 14.68 CNY 0.89% Market Closed
Market Cap: 14B CNY

Pacific Shuanglin Bio pharmacy Co Ltd
Other Operating Expenses

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Pacific Shuanglin Bio pharmacy Co Ltd
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
P
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Other Operating Expenses
¥12.3m
CAGR 3-Years
N/A
CAGR 5-Years
44%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Operating Expenses
¥201.6m
CAGR 3-Years
16%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Other Operating Expenses
-¥396.6m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Other Operating Expenses
-¥102.3m
CAGR 3-Years
N/A
CAGR 5-Years
-14%
CAGR 10-Years
N/A
3SBio Inc
HKEX:1530
Other Operating Expenses
¥105.2m
CAGR 3-Years
36%
CAGR 5-Years
61%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Other Operating Expenses
¥66.4m
CAGR 3-Years
58%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pacific Shuanglin Bio pharmacy Co Ltd
Glance View

Market Cap
14B CNY
Industry
Biotechnology

In the intricate web of China's burgeoning pharmaceutical landscape, Pacific Shuanglin Bio-Pharmacy Co., Ltd. stands out as a dynamic entity making waves in the biopharmaceutical sector. Founded with a vision to innovate and provide advanced healthcare solutions, the company has anchored its operations in the research, development, manufacturing, and marketing of a diverse range of bio-products and pharmaceutical drugs. The core of their business revolves around biotechnology, leveraging cutting-edge techniques to develop treatments aimed at addressing critical and complex health issues. Their product portfolio is robust, comprising antibiotics, cardiovascular medications, and other critical therapeutic areas, which emphasizes their capacity to adapt and thrive in a competitive market. Central to Pacific Shuanglin's success is its steadfast commitment to research and innovation. By investing heavily in R&D, the company not only ensures a steady pipeline of new products but also enhances the efficacy and safety of existing ones. This strategic focus not only stimulates growth but also fortifies their competitive edge. Their revenue model predominantly hinges on the successful commercialization of these pharmaceutical innovations, reinforcing a cycle of continual improvement and reinvestment in new medical solutions. Through strategic partnerships and a well-established distribution network, Pacific Shuanglin effectively reaches its target markets, both domestically and internationally, ensuring that their advanced medical products make a tangible difference in the lives of patients.

Pacific Shuanglin Bio pharmacy Co Ltd Intrinsic Value
HIDDEN
Show

See Also

What is Pacific Shuanglin Bio pharmacy Co Ltd's Other Operating Expenses?
Other Operating Expenses
12.3m CNY

Based on the financial report for Sep 30, 2025, Pacific Shuanglin Bio pharmacy Co Ltd's Other Operating Expenses amounts to 12.3m CNY.

What is Pacific Shuanglin Bio pharmacy Co Ltd's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
44%

Over the last year, the Other Operating Expenses growth was 7%.

Back to Top